Coherence Neuro develops implantable bioelectronic therapies designed to target pathological electrical signaling in cancer. The company’s lead system, SOMA-1, is implanted during glioblastoma surgery and interfaces directly with brain tissue surrounding the tumor. Its approach focuses on addressing the electrical activity that contributes to tumor growth and invasion. Coherence Neuro positions its technology within regulated surgical and oncological care pathways.

The technology continuously monitors electrical signals in the tumor microenvironment following implantation. By detecting and disrupting abnormal bioelectrical patterns associated with tumor progression, the system aims to interfere with signaling mechanisms that support cancer growth. This approach represents a form of precision bioelectronic therapy, combining sensing and intervention at the site of disease. The implant is designed for ongoing operation after surgery rather than one-time intraoperative use.

Coherence Neuro targets glioblastoma, an aggressive brain cancer with limited treatment options and poor prognosis. The platform is intended to complement existing surgical, chemotherapeutic, and radiological interventions. Its positioning reflects emerging interest in the role of bioelectrical signaling in oncology and the potential of implantable neurotechnology to modulate disease-driving neural and cellular processes.